1
|
Sailleau C, Postic L, Chatenet X, Salat O, Turpaud M, Durand B, Vitour D, Zientara S, Bréard E. Serological Responses in Cattle following Booster Vaccination against Serotypes 4 and 8 Bluetongue Virus with Two Bivalent Commercial Inactivated Vaccines. Viruses 2022; 14:v14122719. [PMID: 36560723 PMCID: PMC9781302 DOI: 10.3390/v14122719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Revised: 11/21/2022] [Accepted: 11/30/2022] [Indexed: 12/12/2022] Open
Abstract
Since the outbreak of bluetongue in Northern Europe in 2006, numerous outbreaks involving several serotypes have been observed. Since 2008, compulsory or voluntary vaccination campaigns with inactivated vaccines have been carried out to eradicate these serotypes. In France, serotypes 8 and 4 have been enzootic since 2017, and currently, the majority of vaccinations take place in the context of animal movements, to comply with the regulations of the importing countries. Several vaccine manufacturers have developed inactivated vaccines against serotypes 4 and 8 (mono or bivalent). In this study, we investigated and compared the serological responses to a booster vaccination with two different bivalent inactivated vaccines (BTVPUR suspension injectable® 4 + 8, Boehringer Ingelheim or SYVAZUL ® BTV 4 + 8, Biové) following a primary vaccination with BTVPUR® 4 + 8 in the previous year. The results show that using an alternative vaccine for booster vaccination is at least as effective as using the homologous vaccine. Indeed, the antibody response against BTV-8 is higher in the case of a heterologous vaccination and identical for BTV-4. This information could allow more flexibility in the choice of vaccines used for booster vaccination, particularly in cases where homologous vaccines are in short supply or unavailable.
Collapse
Affiliation(s)
- Corinne Sailleau
- UMR VIROLOGIE, INRAE, École Nationale Vétérinaire d’Alfort, ANSES Laboratoire de Santé Animale, Université Paris-Est, 94700 Maisons-Alfort, France
- Correspondence:
| | - Lydie Postic
- UMR VIROLOGIE, INRAE, École Nationale Vétérinaire d’Alfort, ANSES Laboratoire de Santé Animale, Université Paris-Est, 94700 Maisons-Alfort, France
| | | | - Olivier Salat
- Commissions Vaches Laitières et Qualité du Lait de la SNGTV, Clinique Vétérinaire de la Haute Auvergne, 15100 Saint Flour, France
| | - Mathilde Turpaud
- UMR VIROLOGIE, INRAE, École Nationale Vétérinaire d’Alfort, ANSES Laboratoire de Santé Animale, Université Paris-Est, 94700 Maisons-Alfort, France
| | - Benoit Durand
- Epidemiology Unit, Laboratory for Animal Health, French Agency for Food, Environmental and Occupational Health and Safety (ANSES), University Paris-Est, 94700 Maisons-Alfort, France
| | - Damien Vitour
- UMR VIROLOGIE, INRAE, École Nationale Vétérinaire d’Alfort, ANSES Laboratoire de Santé Animale, Université Paris-Est, 94700 Maisons-Alfort, France
| | - Stéphan Zientara
- UMR VIROLOGIE, INRAE, École Nationale Vétérinaire d’Alfort, ANSES Laboratoire de Santé Animale, Université Paris-Est, 94700 Maisons-Alfort, France
| | - Emmanuel Bréard
- UMR VIROLOGIE, INRAE, École Nationale Vétérinaire d’Alfort, ANSES Laboratoire de Santé Animale, Université Paris-Est, 94700 Maisons-Alfort, France
| |
Collapse
|
2
|
Bamouh Z, Es-Sadeqy Y, Safini N, Douieb L, Omari Tadlaoui K, Martínez RV, García MA, Fassi-Fihri O, Elharrak M. Safety and efficacy of a Bluetongue inactivated vaccine (serotypes 1 and 4) in sheep. Vet Microbiol 2021; 261:109212. [PMID: 34450450 DOI: 10.1016/j.vetmic.2021.109212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 08/16/2021] [Indexed: 11/27/2022]
Abstract
A new inactivated vaccine against Bluetongue virus (BTV) serotypes 1 and 4, was developed from field isolates. Safety and efficacy of the vaccine were evaluated in sheep by serological monitoring and virus nucleic acid detection after experimental infection of vaccinated animals. Seroconversion was observed in vaccinated animals at day 14 post vaccination (pv) with neutralizing antibody titer of 1.9 and 1.8 for serotypes 1 and 4, respectively. The titer increase significantly after the booster reaching 2.7 and persist one year >1.5 for both serotypes. After challenge with virulent isolates, vireamia was recorded in control animals, as evident by q-PCR with threshold cycles (Ct) ranging from 24 to 31 and peaked at day 10 post challenge, while no vireamia was detected in vaccinated animals. Vaccinated sheep were fully protected against the disease and infection.
Collapse
Affiliation(s)
- Z Bamouh
- Research and Development, MCI Santé Animale, Lot. 157, Z. I., Sud-Ouest (ERAC) B.P: 278, Mohammedia 28810, Morocco; Institut Agronomique et Vétérinaire Hassan II, Rabat, Morocco.
| | - Y Es-Sadeqy
- Research and Development, MCI Santé Animale, Lot. 157, Z. I., Sud-Ouest (ERAC) B.P: 278, Mohammedia 28810, Morocco.
| | - N Safini
- Research and Development, MCI Santé Animale, Lot. 157, Z. I., Sud-Ouest (ERAC) B.P: 278, Mohammedia 28810, Morocco.
| | - L Douieb
- Research and Development, MCI Santé Animale, Lot. 157, Z. I., Sud-Ouest (ERAC) B.P: 278, Mohammedia 28810, Morocco.
| | - K Omari Tadlaoui
- Research and Development, MCI Santé Animale, Lot. 157, Z. I., Sud-Ouest (ERAC) B.P: 278, Mohammedia 28810, Morocco.
| | | | - M Agüero García
- Laboratorio Central de Veterinaria-Animal Health, Algete, Madrid, Spain.
| | - O Fassi-Fihri
- Institut Agronomique et Vétérinaire Hassan II, Rabat, Morocco.
| | - M Elharrak
- Research and Development, MCI Santé Animale, Lot. 157, Z. I., Sud-Ouest (ERAC) B.P: 278, Mohammedia 28810, Morocco.
| |
Collapse
|
3
|
Saminathan M, Singh KP, Khorajiya JH, Dinesh M, Vineetha S, Maity M, Rahman AF, Misri J, Malik YS, Gupta VK, Singh RK, Dhama K. An updated review on bluetongue virus: epidemiology, pathobiology, and advances in diagnosis and control with special reference to India. Vet Q 2021; 40:258-321. [PMID: 33003985 PMCID: PMC7655031 DOI: 10.1080/01652176.2020.1831708] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Bluetongue (BT) is an economically important, non-contagious viral disease of domestic and wild ruminants. BT is caused by BT virus (BTV) and it belongs to the genus Orbivirus and family Reoviridae. BTV is transmitted by Culicoides midges and causes clinical disease in sheep, white-tailed deer, pronghorn antelope, bighorn sheep, and subclinical manifestation in cattle, goats and camelids. BT is a World Organization for Animal Health (OIE) listed multispecies disease and causes great socio-economic losses. To date, 28 serotypes of BTV have been reported worldwide and 23 serotypes have been reported from India. Transplacental transmission (TPT) and fetal abnormalities in ruminants had been reported with cell culture adopted live-attenuated vaccine strains of BTV. However, emergence of BTV-8 in Europe during 2006, confirmed TPT of wild-type/field strains of BTV. Diagnosis of BT is more important for control of disease and to ensure BTV-free trade of animals and their products. Reverse transcription polymerase chain reaction, agar gel immunodiffusion assay and competitive enzyme-linked immunosorbent assay are found to be sensitive and OIE recommended tests for diagnosis of BTV for international trade. Control measures include mass vaccination (most effective method), serological and entomological surveillance, forming restriction zones and sentinel programs. Major hindrances with control of BT in India are the presence of multiple BTV serotypes, high density of ruminant and vector populations. A pentavalent inactivated, adjuvanted vaccine is administered currently in India to control BT. Recombinant vaccines with DIVA strategies are urgently needed to combat this disease. This review is the first to summarise the seroprevalence of BTV in India for 40 years, economic impact and pathobiology.
Collapse
Affiliation(s)
- Mani Saminathan
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| | - Karam Pal Singh
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| | | | - Murali Dinesh
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| | - Sobharani Vineetha
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| | - Madhulina Maity
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| | - At Faslu Rahman
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| | - Jyoti Misri
- Animal Science Division, Indian Council of Agricultural Research, New Delhi, India
| | - Yashpal Singh Malik
- Division of Biological Standardization, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| | - Vivek Kumar Gupta
- Centre for Animal Disease Research and Diagnosis, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| | - Raj Kumar Singh
- Director, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| | - Kuldeep Dhama
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| |
Collapse
|
4
|
Teffera M, Babiuk S. Potential of Using Capripoxvirus Vectored Vaccines Against Arboviruses in Sheep, Goats, and Cattle. Front Vet Sci 2019; 6:450. [PMID: 31921911 PMCID: PMC6932975 DOI: 10.3389/fvets.2019.00450] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Accepted: 11/27/2019] [Indexed: 11/26/2022] Open
Abstract
The genus capripoxvirus consists of sheeppox virus, goatpox virus, and lumpy skin disease virus, which affect sheep, goats, and cattle, respectively. Together capripoxviruses cause significant economic losses to the sheep, goat, and cattle industry where these diseases are present. These diseases have spread into previously free bordering regions most recently demonstrated with the spread of lumpy skin disease virus into the Middle East, some Eastern European countries, and Russia. This recent spread has highlighted the transboundary nature of these diseases. To control lumpy skin disease virus, live attenuated viral vaccines are used in endemic countries as well as in response to an outbreak. For sheeppox and goatpox, live attenuated viral vaccines are used in endemic countries; these diseases can also be contained through slaughter of infected animals to stamp out the disease. The thermostability, narrow host range, and ability of capripoxviruses to express a wide variety of antigens make capripoxviruses ideal vectors. The ability to immunize animals against multiple diseases simultaneously increases vaccination efficiency by decreasing the number of vaccinations required. Additionally, the use of capripoxvirus vectored vaccines allows the possibility of differentiating infected from vaccinated animals. Arboviruses such as bluetongue virus and Rift Valley fever viruses are also responsible for significant economic losses in endemic countries. In the case of Rift Valley fever virus, vaccination is not routinely practiced unless there is an outbreak making vaccination not as effective, therefore, incorporating Rift Valley fever vaccination into routine capripoxvirus vaccination would be highly beneficial. This review will discuss the potential of using capripoxvirus as a vector expressing protective arboviral antigens.
Collapse
Affiliation(s)
- Mahder Teffera
- Canadian Food Inspection Agency, National Centre for Foreign Animal Disease, Winnipeg, MB, Canada
- Department of Immunology, University of Manitoba, Winnipeg, MB, Canada
| | - Shawn Babiuk
- Canadian Food Inspection Agency, National Centre for Foreign Animal Disease, Winnipeg, MB, Canada
- Department of Immunology, University of Manitoba, Winnipeg, MB, Canada
| |
Collapse
|
5
|
Comparative Evaluation of T-Cell Immune Response to BTV Infection in Sheep Vaccinated with Pentavalent BTV Vaccine When Compared to Un-Vaccinated Animals. Vet Med Int 2019; 2019:8762780. [PMID: 31885849 PMCID: PMC6915004 DOI: 10.1155/2019/8762780] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Revised: 09/09/2019] [Accepted: 09/23/2019] [Indexed: 11/23/2022] Open
Abstract
Recent invasion of multiple bluetongue virus serotypes (BTV) in different regions of the world necessitates urgent development of efficient vaccine that is directed against multiple BTV serotypes. In this experimental study, cell mediated immune response and protective efficacy of binary ethylenimine (BEI) inactivated Montanide™ ISA 206 adjuvanted pentavalent (BTV-1, 2, 10, 16 and 23) vaccine was evaluated in sheep and direct challenge with homologous BTV serotypes in their respective group. Significant (P < 0.05) up-regulation of mRNA transcripts of IFN-α, IL-2, IL-6, IL-12, IFN-γ and TNF-α in PBMCs of vaccinated animals as compared to control (un-vaccinated) animals at certain time points was observed. On the other hand, there was a significant increase in mean ± SD percentage of CD8+ T cells after 7 days post challenge (DPC) but, the mean ± SD percentage of CD4+ T-cell population slightly declined at 7 DPC and enhanced after 14 DPC. Significant differences (P < 0.05) of CD8+ and CD4+T cells population was also observed between vaccinated and unvaccinated sheep. The vaccine also significantly (P < 0.05) reduced BTV RNA load in PBMCs of vaccinated animals than unvaccinated animals following challenge. There were no significant difference (P > 0.05) in cytokine induction, BTV RNA load and CD8+ and CD4+cell count among BTV-1, 2, 10, 16 and 23 serotype challenges except significant increase in mean ± SD percentage of CD8+ in BTV-2 group. These findings put forwarded that binary ethylenimine inactivated montanide adjuvanted pentavalent bluetongue vaccine has stimulated cell mediated immune response and most importantly reduced the severity of BTV-1, 2, 10, 16 and 23 infections following challenge in respective group.
Collapse
|
6
|
van Rijn PA. Prospects of Next-Generation Vaccines for Bluetongue. Front Vet Sci 2019; 6:407. [PMID: 31824966 PMCID: PMC6881303 DOI: 10.3389/fvets.2019.00407] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2019] [Accepted: 11/01/2019] [Indexed: 01/16/2023] Open
Abstract
Bluetongue (BT) is a haemorrhagic disease of wild and domestic ruminants with a huge economic worldwide impact on livestock. The disease is caused by BT-virus transmitted by Culicoides biting midges and disease control without vaccination is hardly possible. Vaccination is the most feasible and cost-effective way to minimize economic losses. Marketed BT vaccines are successfully used in different parts of the world. Inactivated BT vaccines are efficacious and safe but relatively expensive, whereas live-attenuated vaccines are efficacious and cheap but are unsafe because of under-attenuation, onward spread, reversion to virulence, and reassortment events. Both manufactured BT vaccines do not enable differentiating infected from vaccinated animals (DIVA) and protection is limited to the respective serotype. The ideal BT vaccine is a licensed, affordable, completely safe DIVA vaccine, that induces quick, lifelong, broad protection in all susceptible ruminant species. Promising vaccine candidates show improvement for one or more of these main vaccine standards. BTV protein vaccines and viral vector vaccines have DIVA potential depending on the selected BTV antigens, but are less effective and likely more costly per protected animal than current vaccines. Several vaccine platforms based on replicating BTV are applied for many serotypes by exchange of serotype dominant outer shell proteins. These platforms based on one BTV backbone result in attenuation or abortive virus replication and prevent disease by and spread of vaccine virus as well as reversion to virulence. These replicating BT vaccines induce humoral and T-cell mediated immune responses to all viral proteins except to one, which could enable DIVA tests. Most of these replicating vaccines can be produced similarly as currently marketed BT vaccines. All replicating vaccine platforms developed by reverse genetics are classified as genetic modified organisms. This implies extensive and expensive safety trails in target ruminant species, and acceptance by the community could be hindered. Nonetheless, several experimental BT vaccines show very promising improvements and could compete with marketed vaccines regarding their vaccine profile, but none of these next generation BT vaccines have been licensed yet.
Collapse
Affiliation(s)
- Piet A van Rijn
- Department of Virology, Wageningen Bioveterinary Research, Lelystad, Netherlands.,Department of Biochemistry, Centre for Human Metabolomics, North-West University, Potchefstroom, South Africa
| |
Collapse
|
7
|
Red deer ( Cervus elaphus) Did Not Play the Role of Maintenance Host for Bluetongue Virus in France: The Burden of Proof by Long-Term Wildlife Monitoring and Culicoides Snapshots. Viruses 2019; 11:v11100903. [PMID: 31569721 PMCID: PMC6832957 DOI: 10.3390/v11100903] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Accepted: 09/25/2019] [Indexed: 02/07/2023] Open
Abstract
Bluetongue virus (BTV) is a Culicoides-borne pathogen infecting both domestic and wild ruminants. In Europe, the Red Deer (Cervus elaphus) (RD) is considered a potential BTV reservoir, but persistent sylvatic cycle has not yet been demonstrated. In this paper, we explored the dynamics of BTV1 and BTV8 serotypes in the RD in France, and the potential role of that species in the re-emergence of BTV8 in livestock by 2015 (i.e., 5 years after the former last domestic cases). We performed 8 years of longitudinal monitoring (2008–2015) among 15 RD populations and 3065 individuals. We compared Culicoides communities and feeding habits within domestic and wild animal environments (51,380 samples). Culicoides diversity (>30 species) varied between them, but bridge-species able to feed on both wild and domestic hosts were abundant in both situations. Despite the presence of competent vectors in natural environments, BTV1 and BTV8 strains never spread in RD along the green corridors out of the domestic outbreak range. Decreasing antibody trends with no PCR results two years after the last domestic outbreak suggests that seropositive young RD were not recently infected but carried maternal antibodies. We conclude that RD did not play a role in spreading or maintaining BTV in France.
Collapse
|
8
|
Reliable and Standardized Animal Models to Study the Pathogenesis of Bluetongue and Schmallenberg Viruses in Ruminant Natural Host Species with Special Emphasis on Placental Crossing. Viruses 2019; 11:v11080753. [PMID: 31443153 PMCID: PMC6722754 DOI: 10.3390/v11080753] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2019] [Revised: 07/19/2019] [Accepted: 08/13/2019] [Indexed: 01/03/2023] Open
Abstract
Starting in 2006, bluetongue virus serotype 8 (BTV8) was responsible for a major epizootic in Western and Northern Europe. The magnitude and spread of the disease were surprisingly high and the control of BTV improved significantly with the marketing of BTV8 inactivated vaccines in 2008. During late summer of 2011, a first cluster of reduced milk yield, fever, and diarrhoea was reported in the Netherlands. Congenital malformations appeared in March 2012 and Schmallenberg virus (SBV) was identified, becoming one of the very few orthobunyaviruses distributed in Europe. At the start of both epizootics, little was known about the pathogenesis and epidemiology of these viruses in the European context and most assumptions were extrapolated based on other related viruses and/or other regions of the World. Standardized and repeatable models potentially mimicking clinical signs observed in the field are required to study the pathogenesis of these infections, and to clarify their ability to cross the placental barrier. This review presents some of the latest experimental designs for infectious disease challenges with BTV or SBV. Infectious doses, routes of infection, inoculum preparation, and origin are discussed. Particular emphasis is given to the placental crossing associated with these two viruses.
Collapse
|
9
|
Fay PC, Attoui H, Batten C, Mohd Jaafar F, Lomonossoff GP, Daly JM, Mertens PP. Bluetongue virus outer-capsid protein VP2 expressed in Nicotiana benthamiana raises neutralising antibodies and a protective immune response in IFNAR -/- mice. Vaccine X 2019; 2:100026. [PMID: 31384743 PMCID: PMC6668234 DOI: 10.1016/j.jvacx.2019.100026] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2019] [Revised: 04/30/2019] [Accepted: 05/03/2019] [Indexed: 12/31/2022] Open
Abstract
Bluetongue is a severe, economically important disease of ruminants that is widely distributed in tropical and temperate regions around the world. It is associated with major production losses, restrictions of animal movements and trade, as well as costs associated with developing and implementing effective surveillance and control measures. Mammalian hosts infected with bluetongue virus (BTV) generate a protective neutralising antibody response targeting the major BTV outer-capsid protein and serotype-specific antigen, VP2. BTV VP2 proteins that have been expressed in plants are soluble, with a native conformation displaying neutralising epitopes and can assemble with other BTV structural proteins to form virus-like particles (VLPs). His-tagged VP2 proteins of BTV serotypes 4 and 8 were transiently expressed in Nicotiana benthamiana then purified by immobilised metal affinity chromatography (IMAC). Antisera from IFNAR -/- mice prime/boost vaccinated with the purified proteins, were shown to contain VP2-specific antibodies by Indirect ELISA (I-ELISA), western blotting and serum neutralisation tests (SNT). Vaccinated mice, subsequently challenged with either the homologous or heterologous BTV serotype, developed viraemia by day 3 post-infection. However, no clinical signs were observed in mice challenged with the homologous serotype (either prime-boost or single-shot vaccinated), all of which survived for the duration of the study. In contrast, all of the vaccinated mice challenged with a heterologous serotype, died, showing no evidence of cross-protection or suppression of viraemia, as detected by real-time RT-qPCR or virus isolation. The induction of protective, serotype-specific neutralising antibodies in IFNAR -/- mice, indicates potential for the use of plant-expressed BTV VP2s as subunit vaccine components, or as a basis for serotype-specific serological assays.
Collapse
Affiliation(s)
- Petra C. Fay
- The Pirbright Institute, Ash Road, Pirbright, Surrey GU24 0NF, UK
- School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, Leicestershire LE12 5RD, UK
| | - Houssam Attoui
- UMR VIROLOGIE 1161, INRA, Ecole Nationale Vétérinaire d’Alfort, ANSES, Université Paris-Est, Maisons-Alfort F-94700, France
| | - Carrie Batten
- The Pirbright Institute, Ash Road, Pirbright, Surrey GU24 0NF, UK
| | - Fauziah Mohd Jaafar
- UMR VIROLOGIE 1161, INRA, Ecole Nationale Vétérinaire d’Alfort, ANSES, Université Paris-Est, Maisons-Alfort F-94700, France
| | | | - Janet M. Daly
- School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, Leicestershire LE12 5RD, UK
| | - Peter P.C. Mertens
- The Pirbright Institute, Ash Road, Pirbright, Surrey GU24 0NF, UK
- School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, Leicestershire LE12 5RD, UK
| |
Collapse
|
10
|
Bréard E, Gorlier A, Viarouge C, Donnet F, Sailleau C, Schulz C, Hoffmann B, Comtet L, Beer M, Zientara S, Vitour D. Evaluation of an IGM-specific ELISA for early detection of bluetongue virus infections in domestic ruminants sera. Transbound Emerg Dis 2018; 66:537-545. [PMID: 30394662 DOI: 10.1111/tbed.13060] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 09/10/2018] [Accepted: 10/15/2018] [Indexed: 12/01/2022]
Abstract
Competitive-ELISA (c-ELISA) is the most widely used serological test for the detection of Bluetongue virus (BTV) viral protein 7 (VP7) antibodies (Ab). However, these BTV c-ELISAs cannot to distinguish between IgG and IgM. IgM Ab are generated shortly after the primary immune response against an infectious agent, indicating a recent infection or exposure to antigens, such as after vaccination. Because the BTV genome or anti-VP7 Ab can be detected in ruminant blood months after infection, BTV diagnostic tools cannot discriminate between recent and old infections. In this study, we evaluated an IgM-capture ELISA prototype to detect ruminant anti-BTV VP7 IgM on 1,650 serum samples from cattle, sheep, or goats. Animals were BTV-naive, infected, or/and vaccinated with BTV-1, -2, -4, -8, -9, -16, or -27, and we also included 30 sera from cattle infected with the Epizootic haemorrhagic disease virus (EHDV) serotype 6. Results demonstrated that this ELISA kit is specific and can detect the presence of IgM with satisfactory diagnostic specificity and sensitivity from 1 to 5 weeks after BTV infection in domestic ruminants (for goats and cattle; for sheep, at least up to 24 days). The peak of anti-VP7 IgM was reached when the level of infectious viruses and BTV RNA in blood were the highest. The possibility of detecting BTV-RNA in IgM-positive sera allows the amplification and sequencing of the partial RNA segment 2 (encoding the serotype specific to VP2) to determine the causative BTV serotype/strain. Therefore, BTV IgM ELISA can detect the introduction of BTV (or EHDV) in an area with BTV-seropositive domestic animals regardless of their serological BTV status. This approach may also be of particular interest for retrospective epidemiological studies on frozen serum samples.
Collapse
Affiliation(s)
- Emmanuel Bréard
- Laboratoire de Santé Animale d'Alfort, Université Paris Est, ANSES, ENVA, INRA, UMR 1161 VIROLOGIE, Maisons-Alfort, France
| | - Axel Gorlier
- Laboratoire de Santé Animale d'Alfort, Université Paris Est, ANSES, ENVA, INRA, UMR 1161 VIROLOGIE, Maisons-Alfort, France
| | - Cyril Viarouge
- Laboratoire de Santé Animale d'Alfort, Université Paris Est, ANSES, ENVA, INRA, UMR 1161 VIROLOGIE, Maisons-Alfort, France
| | | | - Corinne Sailleau
- Laboratoire de Santé Animale d'Alfort, Université Paris Est, ANSES, ENVA, INRA, UMR 1161 VIROLOGIE, Maisons-Alfort, France
| | - Claudia Schulz
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel, Riems, Germany
| | - Bernd Hoffmann
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel, Riems, Germany
| | | | - Martin Beer
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel, Riems, Germany
| | - Stéphan Zientara
- Laboratoire de Santé Animale d'Alfort, Université Paris Est, ANSES, ENVA, INRA, UMR 1161 VIROLOGIE, Maisons-Alfort, France
| | - Damien Vitour
- Laboratoire de Santé Animale d'Alfort, Université Paris Est, ANSES, ENVA, INRA, UMR 1161 VIROLOGIE, Maisons-Alfort, France
| |
Collapse
|
11
|
Schulz C, Sailleau C, Bréard E, Flannery J, Viarouge C, Zientara S, Beer M, Batten C, Hoffmann B. Experimental infection of sheep, goats and cattle with a bluetongue virus serotype 4 field strain from Bulgaria, 2014. Transbound Emerg Dis 2017; 65:e243-e250. [DOI: 10.1111/tbed.12746] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2017] [Indexed: 11/30/2022]
Affiliation(s)
- C. Schulz
- Friedrich-Loeffler-Institut; Institute of Diagnostic Virology; Greifswald-Insel Riems Germany
| | - C. Sailleau
- Université Paris Est; ANSES, ENVA, INRA; UMR 1161 VIROLOGIE; Laboratoire de Santé Animale d'Alfort; Maisons-Alfort France
| | - E. Bréard
- Université Paris Est; ANSES, ENVA, INRA; UMR 1161 VIROLOGIE; Laboratoire de Santé Animale d'Alfort; Maisons-Alfort France
| | - J. Flannery
- The Pirbright Institute; Non Vesicular Reference Laboratory; Woking UK
| | - C. Viarouge
- Université Paris Est; ANSES, ENVA, INRA; UMR 1161 VIROLOGIE; Laboratoire de Santé Animale d'Alfort; Maisons-Alfort France
| | - S. Zientara
- Université Paris Est; ANSES, ENVA, INRA; UMR 1161 VIROLOGIE; Laboratoire de Santé Animale d'Alfort; Maisons-Alfort France
| | - M. Beer
- Friedrich-Loeffler-Institut; Institute of Diagnostic Virology; Greifswald-Insel Riems Germany
| | - C. Batten
- The Pirbright Institute; Non Vesicular Reference Laboratory; Woking UK
| | - B. Hoffmann
- Friedrich-Loeffler-Institut; Institute of Diagnostic Virology; Greifswald-Insel Riems Germany
| |
Collapse
|
12
|
More S, Bicout D, Bøtner A, Butterworth A, Depner K, Edwards S, Garin-Bastuji B, Good M, Gortázar Schmidt C, Michel V, Miranda MA, Nielsen SS, Raj M, Sihvonen L, Spoolder H, Stegeman JA, Thulke HH, Velarde A, Willeberg P, Winckler C, Mertens P, Savini G, Zientara S, Broglia A, Baldinelli F, Gogin A, Kohnle L, Calistri P. Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): bluetongue. EFSA J 2017; 15:e04957. [PMID: 32625623 PMCID: PMC7010010 DOI: 10.2903/j.efsa.2017.4957] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
A specific concept of strain was developed in order to classify the BTV serotypes ever reported in Europe based on their properties of animal health impact: the genotype, morbidity, mortality, speed of spread, period and geographical area of occurrence were considered as classification parameters. According to this methodology the strain groups identified were (i) the BTV strains belonging to serotypes BTV‐1–24, (ii) some strains of serotypes BTV‐16 and (iii) small ruminant‐adapted strains belonging to serotypes BTV‐25, ‐27, ‐30. Those strain groups were assessed according to the criteria of the Animal Health Law (AHL), in particular criteria of Article 7, Article 5 on the eligibility of bluetongue to be listed, Article 9 for the categorisation according to disease prevention and control rules as in Annex IV and Article 8 on the list of animal species related to bluetongue. The assessment has been performed following a methodology composed of information collection, expert judgement at individual and collective level. The output is composed of the categorical answer, and for the questions where no consensus was reached, the different supporting views are reported. The strain group BTV (1–24) can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL, while the strain group BTV‐25–30 and BTV‐16 cannot. The strain group BTV‐1–24 meets the criteria as in Sections 2 and 5 of Annex IV of the AHL, for the application of the disease prevention and control rules referred to in points (b) and (e) of Article 9(1) of the AHL. The animal species that can be considered to be listed for BTV‐1–24 according to Article 8(3) are several species of Bovidae, Cervidae and Camelidae as susceptible species; domestic cattle, sheep and red deer as reservoir hosts, midges insect of genus Culicoides spp. as vector species.
Collapse
|
13
|
Sailleau C, Breard E, Viarouge C, Gorlier A, Quenault H, Hirchaud E, Touzain F, Blanchard Y, Vitour D, Zientara S. Complete genome sequence of bluetongue virus serotype 4 that emerged on the French island of Corsica in December 2016. Transbound Emerg Dis 2017; 65:e194-e197. [PMID: 28497659 DOI: 10.1111/tbed.12660] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Indexed: 11/29/2022]
Abstract
In November 2016, sheep located in the south of Corsica island exhibited clinical signs suggestive of bluetongue virus (BTV) infection. Laboratory analyses allowed to isolate and identify a BTV strain of serotype 4. The analysis of the full viral genome showed that all the 10 genomic segments were closely related to those of the BTV-4 present in Hungary in 2014 and involved in a large BT outbreak in the Balkan Peninsula. These results together with epidemiological data suggest that BTV-4 has been introduced to Corsica from Italy (Sardinia) where BTV-4 outbreaks have been reported in autumn 2016. This is the first report of the introduction in Corsica of a BTV strain previously spreading in eastern Europe.
Collapse
Affiliation(s)
- C Sailleau
- UMR 1161 ANSES/INRA/ENVA, Université Paris-Est ANSES Alfort, Maisons-Alfort, France
| | - E Breard
- UMR 1161 ANSES/INRA/ENVA, Université Paris-Est ANSES Alfort, Maisons-Alfort, France
| | - C Viarouge
- UMR 1161 ANSES/INRA/ENVA, Université Paris-Est ANSES Alfort, Maisons-Alfort, France
| | - A Gorlier
- UMR 1161 ANSES/INRA/ENVA, Université Paris-Est ANSES Alfort, Maisons-Alfort, France
| | - H Quenault
- Unit of Viral Genetics and Biosafety, Laboratory of Ploufragan, Anses, Ploufragan, France
| | - E Hirchaud
- Unit of Viral Genetics and Biosafety, Laboratory of Ploufragan, Anses, Ploufragan, France
| | - F Touzain
- Unit of Viral Genetics and Biosafety, Laboratory of Ploufragan, Anses, Ploufragan, France
| | - Y Blanchard
- Unit of Viral Genetics and Biosafety, Laboratory of Ploufragan, Anses, Ploufragan, France
| | - D Vitour
- UMR 1161 ANSES/INRA/ENVA, Université Paris-Est ANSES Alfort, Maisons-Alfort, France
| | - S Zientara
- UMR 1161 ANSES/INRA/ENVA, Université Paris-Est ANSES Alfort, Maisons-Alfort, France
| |
Collapse
|
14
|
Mayo C, Lee J, Kopanke J, MacLachlan NJ. A review of potential bluetongue virus vaccine strategies. Vet Microbiol 2017; 206:84-90. [PMID: 28377132 DOI: 10.1016/j.vetmic.2017.03.015] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2016] [Revised: 03/03/2017] [Accepted: 03/14/2017] [Indexed: 10/19/2022]
Abstract
Bluetongue (BT) is an economically important, non-zoonotic arboviral disease of certain wild and domestic species of cloven-hooved ungulates. Bluetongue virus (BTV) is the causative agent and the occurrence of BTV infection is distinctly seasonal in temperate regions of the world, and dependent on the presence of vector biting midges (e.g. Culicoides sonorensis in much of North America). In recent years, severe outbreaks have occurred throughout Europe and BTV is endemic in most tropical and temperate regions of the world. Several vaccines have been licensed for commercial use, including modified live (live-attenuated) and inactivated products, and this review summarizes recent strategies developed for BTV vaccines with emphasis on technologies suitable for differentiating naturally infected from vaccinated animals. The goal of this review is to evaluate realistic vaccine strategies that might be utilized to control or prevent future outbreaks of BT.
Collapse
Affiliation(s)
- Christie Mayo
- Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80526, United States.
| | - Justin Lee
- Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80526, United States
| | - Jennifer Kopanke
- Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80526, United States
| | - N James MacLachlan
- Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California, Davis, CA 95616, United States
| |
Collapse
|
15
|
Abstract
The performance of different bluetongue control measures related to both vaccination and protection from bluetongue virus (BTV) vectors was assessed. By means of a mathematical model, it was concluded that when vaccination is applied on 95% of animals even for 3 years, bluetongue cannot be eradicated and is able to re‐emerge. Only after 5 years of vaccination, the infection may be close to the eradication levels. In the absence of vaccination, the disease can persist for several years, reaching an endemic condition with low level of prevalence of infection. Among the mechanisms for bluetongue persistence, the persistence in the wildlife, the transplacental transmission in the host, the duration of viraemia and the possible vertical transmission in vectors were assessed. The criteria of the current surveillance scheme in place in the EU for demonstration of the virus absence need revision, because it was highlighted that under the current surveillance policy bluetongue circulation might occur undetected. For the safe movement of animals, newborn ruminants from vaccinated mothers with neutralising antibodies can be considered protected against infection, although a protective titre threshold cannot be identified. The presence of colostral antibodies interferes with the vaccine immunisation in the newborn for more than 3 months after birth, whereas the minimum time after vaccination of animal to be considered immune can be up to 48 days. The knowledge about vectors ecology, mechanisms of over‐wintering and criteria for the seasonally vector‐free period was updated. Some Culicoides species are active throughout the year and an absolute vector‐free period may not exist at least in some areas in Europe. To date, there is no evidence that the use of insecticides and repellents reduce the transmission of BTV in the field, although this may reduce host/vector contact. By only using pour‐on insecticides, protection of animals is lower than the one provided by vector‐proof establishments. This publication is linked to the following EFSA Supporting Publications article: http://onlinelibrary.wiley.com/doi/10.2903/sp.efsa.2017.EN-1182/full, http://onlinelibrary.wiley.com/doi/10.2903/sp.efsa.2017.EN-1171/full
Collapse
|
16
|
Abstract
Bluetongue virus (BTV) is the type species of genus Orbivirus within family Reoviridae. Bluetongue virus is transmitted between its ruminant hosts by the bite of Culicoides spp. midges. Severe BT cases are characterized by symptoms including hemorrhagic fever, particularly in sheep, loss of productivity, and death. To date, 27 BTV serotypes have been documented. These include novel isolates of atypical BTV, which have been almost fully characterized using deep sequencing technologies and do not rely on Culicoides vectors for their transmission among hosts. Due to its high economic impact, BT is an Office International des Epizooties (OIE) listed disease that is strictly controlled in international commercial exchanges. During the 20th century, BTV has been endemic in subtropical regions. In the last 15 years, novel strains of nine "typical" BTV serotypes (1, 2, 4, 6, 8, 9, 11, 14, and 16) invaded Europe, some of which caused disease in naive sheep and unexpectedly in bovine herds (particularly serotype 8). Over the past few years, three novel "atypical" serotypes (25-27) were characterized during sequencing studies of animal samples from Switzerland, Kuwait, and France, respectively. Classical serotype-specific inactivated vaccines, although expensive, were very successful in controlling outbreaks as shown with the northern European BTV-8 outbreak which started in the summer of 2006. Technological jumps in deep sequencing methodologies made rapid full characterizations of BTV genome from isolates/tissues feasible. Next-generation sequencing (NGS) approaches are powerful tools to study the variability of BTV genomes on a fine scale. This paper provides information on how NGS impacted our knowledge of the BTV genome.
Collapse
|
17
|
Spedicato M, Lorusso A, Salini R, Gennaro AD, Leone A, Teodori L, Casaccia C, Portanti O, Calistri P, Giovannini A, Savini G. Efficacy of vaccination for bluetongue virus serotype 8 performed shortly before challenge and implications for animal trade. Prev Vet Med 2017; 136:49-55. [DOI: 10.1016/j.prevetmed.2016.11.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Revised: 10/21/2016] [Accepted: 11/21/2016] [Indexed: 11/28/2022]
|
18
|
Bitew M, Nandi S, Ravishanka C, Sharma A. Humoral Immune Response and Protective Efficacy of Binary Ethylenimine (BEI) Inactivated Pentavalent Bluetongue Vaccine after Challenge with Homologous Virus in Sheep. ACTA ACUST UNITED AC 2016. [DOI: 10.3923/ijv.2017.43.52] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
19
|
Breard E, Garnier A, Despres P, Blaise Boisseau S, Comtet L, Viarouge C, Bakkali-Kassimi L, Pourquier P, Hudelet P, Vitour D, Rossi S, Belbis G, Sailleau C, Zientara S. Development of a Double-Antigen Microsphere Immunoassay for Simultaneous Group and Serotype Detection of Bluetongue Virus Antibodies. Transbound Emerg Dis 2016; 64:1837-1847. [PMID: 27667484 DOI: 10.1111/tbed.12578] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Indexed: 11/30/2022]
Abstract
Bluetongue viruses (BTV) are arboviruses responsible for infections in ruminants. The confirmation of BTV infections is based on rapid serological tests such as enzyme-linked immunosorbent assays (ELISAs) using the BTV viral protein 7 (VP7) as antigen. The determination of the BTV serotype by serological analyses could be only performed by neutralization tests (VNT) which are time-consuming and require BSL3 facilities. VP2 protein is considered the major serotype-defining protein of BTV. To improve the serological characterization of BTV infections, the recombinant VP7 and BTV serotype 8 (BTV-8) VP2 were synthesized using insect cells expression system. The purified antigens were covalently bound to fluorescent beads and then assayed with 822 characterized ruminant sera from BTV vaccinations or infections in a duplex microsphere immunoassay (MIA). The revelation step of this serological duplex assay was performed with biotinylated antigens instead of antispecies conjugates to use it on different ruminant species. The results demonstrated that MIA detected the anti-VP7 antibodies with a high specificity as well as a competitive ELISA approved for BTV diagnosis, with a better efficiency for the early detection of the anti-VP7 antibodies. The VP2 MIA results showed that this technology is also an alternative to VNT for BTV diagnosis. Comparisons between the VP2 MIA and VNT results showed that VNT detects the anti-VP2 antibodies in an early stage and that the VP2 MIA is as specific as VNT. This novel immunoassay provides a platform for developing multiplex assays, in which the presence of antibodies against multiple BTV serotypes can be detected simultaneously.
Collapse
Affiliation(s)
- E Breard
- UMR 1161 VIROLOGIE ANSES-INRA-ENVA, Université Paris Est, ANSES, Maisons-Alfort, France
| | - A Garnier
- UMR 1161 VIROLOGIE ANSES-INRA-ENVA, Université Paris Est, ANSES, Maisons-Alfort, France
| | - P Despres
- UMR PIMIT (I2T), Université de La Réunion, INSERM U1187, CNRS 9192, IRD 249, technology platform CYROI, Saint-Clotilde, La Reunion, France
| | - S Blaise Boisseau
- UMR 1161 VIROLOGIE ANSES-INRA-ENVA, Université Paris Est, ANSES, Maisons-Alfort, France
| | | | - C Viarouge
- UMR 1161 VIROLOGIE ANSES-INRA-ENVA, Université Paris Est, ANSES, Maisons-Alfort, France
| | - L Bakkali-Kassimi
- UMR 1161 VIROLOGIE ANSES-INRA-ENVA, Université Paris Est, ANSES, Maisons-Alfort, France
| | | | | | - D Vitour
- UMR 1161 VIROLOGIE ANSES-INRA-ENVA, Université Paris Est, ANSES, Maisons-Alfort, France
| | - S Rossi
- Unité Sanitaire de la Faune, Office National de la Chasse et de la Faune Sauvage, Gap, France
| | - G Belbis
- Unité de Pathologie du Bétail, Ecole Nationale Vétérinaire d'Alfort, Université Paris-Est, Maisons-Alfort, France
| | - C Sailleau
- UMR 1161 VIROLOGIE ANSES-INRA-ENVA, Université Paris Est, ANSES, Maisons-Alfort, France
| | - S Zientara
- UMR 1161 VIROLOGIE ANSES-INRA-ENVA, Université Paris Est, ANSES, Maisons-Alfort, France
| |
Collapse
|
20
|
Hanon JB, Vandenberge V, Deruelle M, De Leeuw I, De Clercq K, Van Borm S, Koenen F, Liu L, Hoffmann B, Batten CA, Zientara S, Breard E, Van der Stede Y. Inter-laboratory evaluation of the performance parameters of a Lateral Flow Test device for the detection of Bluetongue virus-specific antibodies. J Virol Methods 2015; 228:140-50. [PMID: 26687976 DOI: 10.1016/j.jviromet.2015.12.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2015] [Revised: 11/23/2015] [Accepted: 12/01/2015] [Indexed: 12/01/2022]
Abstract
Bluetongue (BT) is a viral vector-borne disease affecting domestic and wild ruminants worldwide. In this study, a commercial rapid immuno-chromatographic method or Lateral Flow Test (LFT) device, for the detection of BT virus-specific antibodies in animal serum, was evaluated in an international inter-laboratory proficiency test. The evaluation was done with sera samples of variable background (ruminant species, serotype, field samples, experimental infections, vaccinated animals). The diagnostic sensitivity was 100% (95% C.I. [90.5-100]) and the diagnostic specificity was 95.2% (95% C.I. [76.2-99.9]). The repeatability (accordance) and reproducibility (concordance) were 100% for seropositive samples but were lower for two of the seronegative samples (45% and 89% respectively). The analytical sensitivity, evaluated by testing positive sera at increasing dilutions was better for the BT LFT compared to some commercial ELISAs. Seroconversion of an infected sheep was detected at 4 days post infection. Analytical specificity was impaired by cross-reactions observed with some of the samples seropositive for Epizootic Haemorrhagic Disease Virus (EHDV). The agreement (Cohen's kappa) between the LFT and a commercial BT competitive ELISA was 0.79 (95% CI [0.62-0.95]). Based on these results, it can be concluded that the BT LFT device is a rapid and sensitive first-line serological test that can be used in the field, especially in areas endemic for the disease where there is a lack of diagnostic facilities.
Collapse
Affiliation(s)
- Jean-Baptiste Hanon
- Veterinary and Agrochemical Research Centre (CODA-CERVA), Coordination of the Veterinary Diagnostic, Epidemiology and Risk Analysis Unit (CDV-ERA), Groeselenberg 99, 1180 Brussels, Belgium.
| | - Valerie Vandenberge
- Veterinary and Agrochemical Research Centre (CODA-CERVA), Coordination of the Veterinary Diagnostic, Epidemiology and Risk Analysis Unit (CDV-ERA), Groeselenberg 99, 1180 Brussels, Belgium
| | - Matthias Deruelle
- Veterinary and Agrochemical Research Centre (CODA-CERVA), Coordination of the Veterinary Diagnostic, Epidemiology and Risk Analysis Unit (CDV-ERA), Groeselenberg 99, 1180 Brussels, Belgium
| | - Ilse De Leeuw
- Veterinary and Agrochemical Research Centre (CODA-CERVA), Vesicular and Exotic Diseases Unit, National Reference Laboratory for Bluetongue, Groeselenberg 99, 1180 Brussels, Belgium
| | - Kris De Clercq
- Veterinary and Agrochemical Research Centre (CODA-CERVA), Vesicular and Exotic Diseases Unit, National Reference Laboratory for Bluetongue, Groeselenberg 99, 1180 Brussels, Belgium
| | - Steven Van Borm
- Veterinary and Agrochemical Research Centre (CODA-CERVA), Molecular Platform Unit, Groeselenberg 99, 1180 Brussels, Belgium
| | - Frank Koenen
- Veterinary and Agrochemical Research Centre (CODA-CERVA), Coordination of the Veterinary Diagnostic, Epidemiology and Risk Analysis Unit (CDV-ERA), Groeselenberg 99, 1180 Brussels, Belgium
| | - Lihong Liu
- National Veterinary Institute (SVA), Department of Virology, Immunobiology and Parasitology (VIP), SE-751 89 Uppsala, Sweden
| | - Bernd Hoffmann
- Friedrich-Loeffler-Institut (FLI), Institute of Diagnostic Virology, Südufer 10, 17493 Greifswald-Insel Riems, Germany
| | - Carrie Anne Batten
- The Pirbright Institute, Non Vesicular Reference Laboratory, Ash Road, Pirbright, Woking GU240NF, United Kingdom
| | - Stéphan Zientara
- Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), UPE, UMR Anses, INRA, ENVA, 14 rue Pierre et Marie Curie, laboratoire de santé animale, Maisons-Alfort, France
| | - Emmanuel Breard
- Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), UPE, UMR Anses, INRA, ENVA, 14 rue Pierre et Marie Curie, laboratoire de santé animale, Maisons-Alfort, France
| | - Yves Van der Stede
- Veterinary and Agrochemical Research Centre (CODA-CERVA), Coordination of the Veterinary Diagnostic, Epidemiology and Risk Analysis Unit (CDV-ERA), Groeselenberg 99, 1180 Brussels, Belgium; Ghent University, Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Salisburylaan 133, 9820 Merelbeke, Belgium
| |
Collapse
|
21
|
Zhugunissov K, Yershebulov Z, Barakbayev K, Bulatov Y, Taranov D, Amanova Z, Abduraimov Y. Duration of protective immunity after a single vaccination with a live attenuated bivalent bluetongue vaccine. Vet Res Commun 2015; 39:203-10. [PMID: 26280208 PMCID: PMC4643103 DOI: 10.1007/s11259-015-9643-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Accepted: 08/11/2015] [Indexed: 11/03/2022]
Abstract
The prevention of bluetongue is typically achieved with mono- or polyvalent modified- live-attenuated virus (MLV) vaccines. MLV vaccines typically elicit a strong antibody response that correlates directly with their ability to replicate in the vaccinated animal. They are inexpensive, stimulate protective immunity after a single inoculation, and have been proven effective in preventing clinical bluetongue disease. In this study, we evaluated the safety, immunogenicity, and efficacy of a bluetongue vaccine against Bluetongue virus serotypes 4 and 16 in sheep. All the animals remained clinically healthy during the observation period. The vaccinated animals showed no clinical signs except fever (>40.8 °C) for 2-4 days. Rapid seroconversion was observed in the sheep, with the accumulation of high antibody titers in the vaccinated animals. No animal became ill after the challenge, indicating that effective protection was achieved. Therefore, this vaccine, prepared from attenuated bluetongue virus strains, is safe, immunogenic, and efficacious.
Collapse
Affiliation(s)
- Kuandyk Zhugunissov
- Research Institute for Biological Safety Problems, Gvardeiskiy, Kordai Raion, 080409, Zhambyl Oblast, Republic of Kazakhstan.
| | - Zakir Yershebulov
- Research Institute for Biological Safety Problems, Gvardeiskiy, Kordai Raion, 080409, Zhambyl Oblast, Republic of Kazakhstan
| | - Kainar Barakbayev
- Research Institute for Biological Safety Problems, Gvardeiskiy, Kordai Raion, 080409, Zhambyl Oblast, Republic of Kazakhstan
| | - Yerbol Bulatov
- Research Institute for Biological Safety Problems, Gvardeiskiy, Kordai Raion, 080409, Zhambyl Oblast, Republic of Kazakhstan
| | - Dmitriy Taranov
- Research Institute for Biological Safety Problems, Gvardeiskiy, Kordai Raion, 080409, Zhambyl Oblast, Republic of Kazakhstan
| | - Zhanat Amanova
- Research Institute for Biological Safety Problems, Gvardeiskiy, Kordai Raion, 080409, Zhambyl Oblast, Republic of Kazakhstan
| | - Yergali Abduraimov
- Research Institute for Biological Safety Problems, Gvardeiskiy, Kordai Raion, 080409, Zhambyl Oblast, Republic of Kazakhstan
| |
Collapse
|
22
|
Breard E, Belbis G, Viarouge C, Nomikou K, Haegeman A, De Clercq K, Hudelet P, Hamers C, Moreau F, Lilin T, Durand B, Mertens P, Vitour D, Sailleau C, Zientara S. Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines. Vaccine 2014; 33:512-8. [PMID: 25500308 DOI: 10.1016/j.vaccine.2014.11.053] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2013] [Revised: 11/20/2014] [Accepted: 11/28/2014] [Indexed: 11/18/2022]
Abstract
Eradication of bluetongue virus is possible, as has been shown in several European countries. New serotypes have emerged, however, for which there are no specific commercial vaccines. This study addressed whether heterologous vaccines would help protect against 2 serotypes. Thirty-seven sheep were randomly allocated to 7 groups of 5 or 6 animals. Four groups were vaccinated with commercial vaccines against BTV strains 2, 4, and 9. A fifth positive control group was given a vaccine against BTV-8. The other 2 groups were unvaccinated controls. Sheep were then challenged by subcutaneous injection of either BTV-16 (2 groups) or BTV-8 (5 groups). Taken together, 24/25 sheep from the 4 experimental groups developed detectable antibodies against the vaccinated viruses. Furthermore, sheep that received heterologous vaccines showed significantly reduced viraemia and clinical scores for BTV-16 when compared to unvaccinated controls. Reductions in clinical signs and viraemia among heterologously vaccinated sheep were not as common after challenge with BTV-8. This study shows that heterologous protection can occur, but that it is difficult to predict if partial or complete protection will be achieved following inactivated-BTV vaccination.
Collapse
Affiliation(s)
- Emmanuel Breard
- ANSES, UMR 1161 Virologie ANSES-INRA-ENVA, 23 avenue du Général de Gaulle, 94704 Maisons-Alfort, France.
| | - Guillaume Belbis
- Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, Unité de Pathologie du Bétail, 7 avenue du Général de Gaulle, 94704 Maisons-Alfort, France
| | - Cyril Viarouge
- ANSES, UMR 1161 Virologie ANSES-INRA-ENVA, 23 avenue du Général de Gaulle, 94704 Maisons-Alfort, France
| | - Kyriaki Nomikou
- Vector-Borne Diseases Programme, The Pirbright Institute, Pirbright, Woking, Surrey GU24 0NF, United Kingdom
| | | | | | - Pascal Hudelet
- MERIAL S.A.S., 254 Rue Marcel Mérieux, 69007 Lyon, France
| | - Claude Hamers
- MERIAL S.A.S., P.I. Plaine de l'Ain, Allée des Cyprès, 01150 Saint-Vulbas, France
| | - Francis Moreau
- Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, Centre de recherche biomédicale, 7 avenue du Général de Gaulle, 94704 Maisons-Alfort, France
| | - Thomas Lilin
- Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, Centre de recherche biomédicale, 7 avenue du Général de Gaulle, 94704 Maisons-Alfort, France
| | - Benoit Durand
- ANSES, unité Epidémiologie, 23 avenue du Général de Gaulle, 94704 Maisons-Alfort, France
| | - Peter Mertens
- Vector-Borne Diseases Programme, The Pirbright Institute, Pirbright, Woking, Surrey GU24 0NF, United Kingdom
| | - Damien Vitour
- ANSES, UMR 1161 Virologie ANSES-INRA-ENVA, 23 avenue du Général de Gaulle, 94704 Maisons-Alfort, France
| | - Corinne Sailleau
- ANSES, UMR 1161 Virologie ANSES-INRA-ENVA, 23 avenue du Général de Gaulle, 94704 Maisons-Alfort, France
| | - Stéphan Zientara
- ANSES, UMR 1161 Virologie ANSES-INRA-ENVA, 23 avenue du Général de Gaulle, 94704 Maisons-Alfort, France
| |
Collapse
|
23
|
Bouet-Cararo C, Contreras V, Caruso A, Top S, Szelechowski M, Bergeron C, Viarouge C, Desprat A, Relmy A, Guibert JM, Dubois E, Thiery R, Bréard E, Bertagnoli S, Richardson J, Foucras G, Meyer G, Schwartz-Cornil I, Zientara S, Klonjkowski B. Expression of VP7, a Bluetongue virus group specific antigen by viral vectors: analysis of the induced immune responses and evaluation of protective potential in sheep. PLoS One 2014; 9:e111605. [PMID: 25364822 PMCID: PMC4218782 DOI: 10.1371/journal.pone.0111605] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2012] [Accepted: 10/06/2014] [Indexed: 11/29/2022] Open
Abstract
Bluetongue virus (BTV) is an economically important Orbivirus transmitted by biting midges to domestic and wild ruminants. The need for new vaccines has been highlighted by the occurrence of repeated outbreaks caused by different BTV serotypes since 1998. The major group-reactive antigen of BTV, VP7, is conserved in the 26 serotypes described so far, and its role in the induction of protective immunity has been proposed. Viral-based vectors as antigen delivery systems display considerable promise as veterinary vaccine candidates. In this paper we have evaluated the capacity of the BTV-2 serotype VP7 core protein expressed by either a non-replicative canine adenovirus type 2 (Cav-VP7 R0) or a leporipoxvirus (SG33-VP7), to induce immune responses in sheep. Humoral responses were elicited against VP7 in almost all animals that received the recombinant vectors. Both Cav-VP7 R0 and SG33-VP7 stimulated an antigen-specific CD4+ response and Cav-VP7 R0 stimulated substantial proliferation of antigen-specific CD8+ lymphocytes. Encouraged by the results obtained with the Cav-VP7 R0 vaccine vector, immunized animals were challenged with either the homologous BTV-2 or the heterologous BTV-8 serotype and viral burden in plasma was followed by real-time RT-PCR. The immune responses triggered by Cav-VP7 R0 were insufficient to afford protective immunity against BTV infection, despite partial protection obtained against homologous challenge. This work underscores the need to further characterize the role of BTV proteins in cross-protective immunity.
Collapse
Affiliation(s)
| | - Vanessa Contreras
- Virologie et Immunologie Moléculaires, UR 892 INRA, Jouy-en-Josas, France
| | - Agathe Caruso
- INRA, UMR1225, IHAP, Université de Toulouse, INP, ENVT, Toulouse, France
| | - Sokunthea Top
- INRA, UMR1225, IHAP, Université de Toulouse, INP, ENVT, Toulouse, France
| | - Marion Szelechowski
- Centre de Physiopathologie de Toulouse Purpan, INSERM U1043, CNRS U5282, Université Paul-Sabatier, Toulouse, France
| | - Corinne Bergeron
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | - Cyril Viarouge
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | - Alexandra Desprat
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | - Anthony Relmy
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | | | - Eric Dubois
- Unité de pathologie des petits ruminants, ANSES, Sophia-Antipolis, France
| | - Richard Thiery
- Unité de pathologie des petits ruminants, ANSES, Sophia-Antipolis, France
| | - Emmanuel Bréard
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | | | | | - Gilles Foucras
- INRA, UMR1225, IHAP, Université de Toulouse, INP, ENVT, Toulouse, France
| | - Gilles Meyer
- INRA, UMR1225, IHAP, Université de Toulouse, INP, ENVT, Toulouse, France
| | | | - Stephan Zientara
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | - Bernard Klonjkowski
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
- * E-mail:
| |
Collapse
|
24
|
Anderson J, Hägglund S, Bréard E, Riou M, Zohari S, Comtet L, Olofson AS, Gélineau R, Martin G, Elvander M, Blomqvist G, Zientara S, Valarcher JF. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle. Vaccine 2014; 32:6614-21. [PMID: 25312275 DOI: 10.1016/j.vaccine.2014.09.066] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Revised: 09/23/2014] [Accepted: 09/29/2014] [Indexed: 11/18/2022]
Abstract
Bluetongue virus (BTV) infections in ruminants pose a permanent agricultural threat since new serotypes are constantly emerging in new locations. Clinical disease is mainly observed in sheep, but cattle were unusually affected during an outbreak of BTV seroype 8 (BTV-8) in Europe. We previously developed an experimental vaccine based on recombinant viral protein 2 (VP2) of BTV-8 and non-structural proteins 1 (NS1) and NS2 of BTV-2, mixed with an immunostimulating complex (ISCOM)-matrix adjuvant. We demonstrated that bovine immune responses induced by this vaccine were as good or superior to those induced by a classic commercial inactivated vaccine. In this study, we evaluated the protective efficacy of the experimental vaccine in cattle and, based on the detection of VP7 antibodies, assessed its DIVA compliancy following virus challenge. Two groups of BTV-seronegative calves were subcutaneously immunized twice at a 3-week interval with the subunit vaccine (n=6) or with adjuvant alone (n=6). Following BTV-8 challenge 3 weeks after second immunization, controls developed viremia and fever associated with other mild clinical signs of bluetongue disease, whereas vaccinated animals were clinically and virologically protected. The vaccine-induced protection was likely mediated by high virus-neutralizing antibody titers directed against VP2 and perhaps by cellular responses to NS1 and NS2. T lymphocyte responses were cross-reactive between BTV-2 and BTV-8, suggesting that NS1 and NS2 may provide the basis of an adaptable vaccine that can be varied by using VP2 of different serotypes. The detection of different levels of VP7 antibodies in vaccinated animals and controls after challenge suggested a compliancy between the vaccine and the DIVA companion test. This BTV subunit vaccine is a promising candidate that should be further evaluated and developed to protect against different serotypes.
Collapse
Affiliation(s)
- Jenna Anderson
- Swedish University of Agricultural Sciences, Host Pathogen Interaction Group, Department of Clinical Sciences, Almas allé 4 C, Uppsala, Sweden
| | - Sara Hägglund
- Swedish University of Agricultural Sciences, Host Pathogen Interaction Group, Department of Clinical Sciences, Almas allé 4 C, Uppsala, Sweden
| | - Emmanuel Bréard
- ANSES, UMR Virologie 1161 ANSES/INRA/ENVA, 23 Avenue Général de Gaulle, Maisons-Alfort, France
| | - Mickaël Riou
- INRA, Centre Val de Loire, UE-1277 Plateforme d'Infectiologie expérimentale (PFIE), Route de Crotelles, Nouzilly, France
| | - Siamak Zohari
- National Veterinary Institute, Department of Virology, Immunology, and Parasitology, Ulls väg 2B, Uppsala, Sweden
| | - Loic Comtet
- IdVet, 167 rue Mehdi Ben Barka, Montpellier, France
| | - Ann-Sophie Olofson
- National Veterinary Institute, Department of Virology, Immunology, and Parasitology, Ulls väg 2B, Uppsala, Sweden
| | - Robert Gélineau
- INRA, Centre Val de Loire, UE-1277 Plateforme d'Infectiologie expérimentale (PFIE), Route de Crotelles, Nouzilly, France
| | - Guillaume Martin
- INRA, Centre Val de Loire, UE-1277 Plateforme d'Infectiologie expérimentale (PFIE), Route de Crotelles, Nouzilly, France
| | - Marianne Elvander
- National Veterinary Institute, Department of Virology, Immunology, and Parasitology, Ulls väg 2B, Uppsala, Sweden
| | - Gunilla Blomqvist
- National Veterinary Institute, Department of Virology, Immunology, and Parasitology, Ulls väg 2B, Uppsala, Sweden
| | - Stéphan Zientara
- ANSES, UMR Virologie 1161 ANSES/INRA/ENVA, 23 Avenue Général de Gaulle, Maisons-Alfort, France
| | - Jean Francois Valarcher
- Swedish University of Agricultural Sciences, Host Pathogen Interaction Group, Department of Clinical Sciences, Almas allé 4 C, Uppsala, Sweden; National Veterinary Institute, Department of Virology, Immunology, and Parasitology, Ulls väg 2B, Uppsala, Sweden.
| |
Collapse
|
25
|
|
26
|
van der Sluijs MTW, de Smit AJ, Moormann RJM. Vector independent transmission of the vector-borne bluetongue virus. Crit Rev Microbiol 2014; 42:57-64. [PMID: 24645633 DOI: 10.3109/1040841x.2013.879850] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Bluetongue is an economically important disease of ruminants. The causative agent, Bluetongue virus (BTV), is mainly transmitted by insect vectors. This review focuses on vector-free BTV transmission, and its epizootic and economic consequences. Vector-free transmission can either be vertical, from dam to fetus, or horizontal via direct contract. For several BTV-serotypes, vertical (transplacental) transmission has been described, resulting in severe congenital malformations. Transplacental transmission had been mainly associated with live vaccine strains. Yet, the European BTV-8 strain demonstrated a high incidence of transplacental transmission in natural circumstances. The relevance of transplacental transmission for the epizootiology is considered limited, especially in enzootic areas. However, transplacental transmission can have a substantial economic impact due to the loss of progeny. Inactivated vaccines have demonstrated to prevent transplacental transmission. Vector-free horizontal transmission has also been demonstrated. Since direct horizontal transmission requires close contact of animals, it is considered only relevant for within-farm spreading of BTV. The genetic determinants which enable vector-free transmission are present in virus strains circulating in the field. More research into the genetic changes which enable vector-free transmission is essential to better evaluate the risks associated with outbreaks of new BTV serotypes and to design more appropriate control measures.
Collapse
Affiliation(s)
| | | | - Rob J M Moormann
- c Central Veterinary Institute , Lelystad , The Netherlands , and.,d Department of Infectious Diseases and Immunology, Virology Division , Utrecht University , Yalelaan , The Netherlands
| |
Collapse
|
27
|
Pioz M, Guis H, Pleydell D, Gay E, Calavas D, Durand B, Ducrot C, Lancelot R. Did vaccination slow the spread of bluetongue in France? PLoS One 2014; 9:e85444. [PMID: 24465562 PMCID: PMC3897431 DOI: 10.1371/journal.pone.0085444] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2013] [Accepted: 11/28/2013] [Indexed: 11/19/2022] Open
Abstract
Vaccination is one of the most efficient ways to control the spread of infectious diseases. Simulations are now widely used to assess how vaccination can limit disease spread as well as mitigate morbidity or mortality in susceptible populations. However, field studies investigating how much vaccines decrease the velocity of epizootic wave-fronts during outbreaks are rare. This study aimed at investigating the effect of vaccination on the propagation of bluetongue, a vector-borne disease of ruminants. We used data from the 2008 bluetongue virus serotype 1 (BTV-1) epizootic of southwest France. As the virus was newly introduced in this area, natural immunity of livestock was absent. This allowed determination of the role of vaccination in changing the velocity of bluetongue spread while accounting for environmental factors that possibly influenced it. The average estimated velocity across the country despite restriction on animal movements was 5.4 km/day, which is very similar to the velocity of spread of the bluetongue virus serotype 8 epizootic in France also estimated in a context of restrictions on animal movements. Vaccination significantly reduced the propagation velocity of BTV-1. In comparison to municipalities with no vaccine coverage, the velocity of BTV-1 spread decreased by 1.7 km/day in municipalities with immunized animals. For the first time, the effect of vaccination has been quantified using data from a real epizootic whilst accounting for environmental factors known to modify the velocity of bluetongue spread. Our findings emphasize the importance of vaccination in limiting disease spread across natural landscape. Finally, environmental factors, specifically those related to vector abundance and activity, were found to be good predictors of the velocity of BTV-1 spread, indicating that these variables need to be adequately accounted for when evaluating the role of vaccination on bluetongue spread.
Collapse
Affiliation(s)
- Maryline Pioz
- Unité Mixte de Recherche Contrôle des Maladies Animales Exotiques et Emergentes, Centre de Coopération Internationale en Recherche Agronomique pour le Développement (CIRAD), Montpellier, France
- Unité Mixte de Recherche 1309 Contrôle des Maladies Animales Exotiques et Emergentes, Institut National de la Recherche Agronomique (INRA), Montpellier, France
- * E-mail:
| | - Hélène Guis
- Unité Mixte de Recherche Contrôle des Maladies Animales Exotiques et Emergentes, Centre de Coopération Internationale en Recherche Agronomique pour le Développement (CIRAD), Montpellier, France
- Unité Mixte de Recherche 1309 Contrôle des Maladies Animales Exotiques et Emergentes, Institut National de la Recherche Agronomique (INRA), Montpellier, France
| | - David Pleydell
- Unité Mixte de Recherche 1309 Contrôle des Maladies Animales Exotiques et Emergentes, Institut National de la Recherche Agronomique (INRA), Petit-Bourg, Guadeloupe, France
- Unité Mixte de Recherche Contrôle des Maladies Animales Exotiques et Emergentes, Centre de Coopération Internationale en Recherche Agronomique pour le Développement (CIRAD), Petit-Bourg, Guadeloupe, France
| | - Emilie Gay
- Unité Epidémiologie, Agence Nationale de Sécurité Sanitaire de l'Alimentation, de l'Environnement et du Travail (ANSES), Lyon, France
| | - Didier Calavas
- Unité Epidémiologie, Agence Nationale de Sécurité Sanitaire de l'Alimentation, de l'Environnement et du Travail (ANSES), Lyon, France
| | - Benoît Durand
- Laboratoire Santé Animale, Agence Nationale de Sécurité Sanitaire de l'Alimentation, de l'Environnement et du Travail (ANSES), Maisons-Alfort, France
| | - Christian Ducrot
- Unité de Recherche 346 d'Epidémiologie Animale, Institut National de la Recherche Agronomique (INRA), Saint Genès Champanelle, France
| | - Renaud Lancelot
- Unité Mixte de Recherche Contrôle des Maladies Animales Exotiques et Emergentes, Centre de Coopération Internationale en Recherche Agronomique pour le Développement (CIRAD), Montpellier, France
- Unité Mixte de Recherche 1309 Contrôle des Maladies Animales Exotiques et Emergentes, Institut National de la Recherche Agronomique (INRA), Montpellier, France
| |
Collapse
|
28
|
Vaccination induces long-lasting neutralising antibodies against bluetongue virus serotypes 1 and 8 in Spanish ibex (Capra pyrenaica). EUR J WILDLIFE RES 2013. [DOI: 10.1007/s10344-013-0783-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
29
|
Vandenbussche F, Sailleau C, Rosseel T, Desprat A, Viarouge C, Richardson J, Eschbaumer M, Hoffmann B, De Clercq K, Bréard E, Zientara S. Full-Genome Sequencing of Four Bluetongue Virus Serotype 11 Viruses. Transbound Emerg Dis 2013; 62:565-71. [PMID: 24750582 DOI: 10.1111/tbed.12178] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2013] [Indexed: 11/29/2022]
Abstract
Recently, a contamination incident was described in which the challenge inoculum used in a bluetongue virus serotype 8 (BTV-8) vaccination trial was contaminated with a BTV-11 virus that was closely related to the Belgian BTV-11 virus from 2008. This study reports the first complete genome sequences of four BTV-11 viruses: the BTV-11 contaminant, BTV-11 reference strain, BTV-11 vaccine strain and a recently isolated BTV-11 field strain from Martinique. Full-genome analysis showed that these viruses belong to serotype 11/nucleotype A and cluster together with other western topotype bluetongue viruses. Detailed comparisons of the genomes further indicated that the contaminant was derived from the BTV-11 reference strain, as they were distinguished by a single synonymous nucleotide substitution. The previously reported partial sequence of genome segment 2 of the Belgian BTV-11 was found to be identical to that of the BTV-11 vaccine strain, indicating that it most likely was the BTV-11 vaccine strain. These findings also suggest that the BTV-11 contaminant and the Belgian BTV-11 are not the same viruses. Finally, comparison of the reference and vaccine strain did not allow determining the amino acid substitutions that contribute to the attenuated phenotype.
Collapse
Affiliation(s)
- F Vandenbussche
- Operational Directorate of Viral Diseases, Molecular Platform, Veterinary and Agrochemical Research Centre, Ukkel, Belgium
| | - C Sailleau
- ANSES, LSA (Animal Health Laboratory) UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | - T Rosseel
- Operational Directorate of Viral Diseases, Molecular Platform, Veterinary and Agrochemical Research Centre, Ukkel, Belgium
| | - A Desprat
- ANSES, LSA (Animal Health Laboratory) UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | - C Viarouge
- ANSES, LSA (Animal Health Laboratory) UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | - J Richardson
- ANSES, LSA (Animal Health Laboratory) UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | - M Eschbaumer
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany
| | - B Hoffmann
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany
| | - K De Clercq
- Operational Directorate of Viral Diseases, Vesicular and Exotic Diseases, Veterinary and Agrochemical Research Centre, Ukkel, Belgium
| | - E Bréard
- ANSES, LSA (Animal Health Laboratory) UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | - S Zientara
- ANSES, LSA (Animal Health Laboratory) UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| |
Collapse
|
30
|
Martinelle L, Dal Pozzo F, Sarradin P, De Leeuw I, De Clercq K, Thys C, Thiry E, Saegerman C. Pulmonary artery haemorrhage in newborn calves following bluetongue virus serotype 8 experimental infections of pregnant heifers. Vet Microbiol 2013; 167:250-9. [PMID: 24035481 DOI: 10.1016/j.vetmic.2013.08.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2013] [Revised: 08/13/2013] [Accepted: 08/19/2013] [Indexed: 11/18/2022]
Abstract
The emergence of bluetongue disease (BT) among livestock in Europe in 2006 raised many questions including the occurrence and epidemiological significance of foetal infections in cattle. To clarify these aspects, vaccinated and unvaccinated pregnant heifers were sequentially infected twice in an isolation facility (biosafety level 3) with a northern European outbreak strain of Bluetongue virus serotype 8 (BTV-8). The study was terminated 2 months after calving with necropsy of the dams and their offspring. The cattle were monitored throughout the study by clinical scoring and for the presence of circulating neutralising antibodies, and after calving for the presence of infectious virus and viral RNA in blood and milk. Four calves, one born from a vaccinated dam and three from non-vaccinated ones, that were infected at 120 days of gestation had obvious haemorrhage of the pulmonary artery at necropsy. Although haemorrhage of the pulmonary artery is highly characteristic of BT, viral RNA was not detected in any of these calves. Furthermore, although none of the calves born from heifers infected prior to mid-gestation had teratogenic BTV typical brain lesions, some had lesions at birth suggestive of in utero BTV infection. Despite the lack of viral RNA detection, the presence of haemorrhage of the pulmonary artery deserves to be reported as a new observation in the context of the multiple investigations having as main subject the BTV placental crossing in cattle.
Collapse
Affiliation(s)
- Ludovic Martinelle
- Research Unit of Epidemiology and Risk Analysis Applied to the Veterinary Sciences (UREAR-ULg), Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, Boulevard de Colonster 20, B-4000 Liège, Belgium
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Breard E, Belbis G, Viarouge C, Riou M, Desprat A, Moreau J, Laloy E, Martin G, Sarradin P, Vitour D, Batten C, Doceul V, Sailleau C, Zientara S. Epizootic hemorrhagic disease virus serotype 6 experimentation on adult cattle. Res Vet Sci 2013; 95:794-8. [PMID: 23899717 DOI: 10.1016/j.rvsc.2013.06.026] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Revised: 06/20/2013] [Accepted: 06/30/2013] [Indexed: 10/26/2022]
Abstract
Epizootic hemorrhagic disease virus (EHDV), an arthropod-borne orbivirus (family Reoviridae), is an emerging pathogen of wild and domestic ruminants closely related to bluetongue virus (BTV). EHDV serotype 6 (EHDV6) has recently caused outbreaks close to Europe in Turkey and Morocco and a recent experimental study performed on calves inoculated with these two EHDV6 strains showed that the young animals have remained clinically unaffected. The aim of this study was to investigate the pathogenicity of an EHDV6 strain from La Reunion Island in adult Holstein (18-month-old heifers). This EHDV6 strain has induced clinical signs in cattle in the field. Samples taken throughout the study were tested with commercially available ELISA and real-time RT-PCR kits. Very mild clinical manifestations were observed in cattle during the experiment although high levels of viral RNA and virus were found in their blood. EHDV was isolated from the blood of infected animals at 8 dpi. Antibodies against EHDV were first detected by 7 dpi and persisted up to the end of the study. Virus was detected in various tissue samples until 35 dpi, but was not infectious. In view of the recent circulation of different arboviruses in Europe, this study demonstrates what the EHD induces a strong viraemia in adult Holstein cattle and shows that a spread of EHD on European livestock cattle is possible.
Collapse
Affiliation(s)
- Emmanuel Breard
- ANSES, UMR 1161 Virologie ANSES-INRA-ENVA, 23 avenue du Général de Gaulle, 94704 Maisons-Alfort, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Evidence of Schmallenberg virus circulation in ruminants in Greece. Trop Anim Health Prod 2013; 46:251-5. [PMID: 23868549 DOI: 10.1007/s11250-013-0449-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/03/2013] [Indexed: 10/26/2022]
Abstract
During March 2013, we investigated the presence and the levels of Schmallenberg virus (SBV) circulation in three dairy cow herds and three sheep flocks in Central Macedonia, Greece. In two cow herds, a high number of abortions had been observed during the winter. Six bulk-tank milk samples and 147 individual sera were screened for SBV-specific antibodies by ELISA. Positive reactions were obtained from 5 out of 6 bulk-tank milk samples, 58 out of 90 sera from the 3 cow herds, and 2 sera from 2 of the 3 sheep flocks. Twenty-two ELISA-positive sera were tested by serum neutralization test (SNT). SNT confirmed the presence of neutralizing antibodies against SBV in all samples tested, with titers ranging between 1:32 and ≥1:256. No neutralizing antibodies against Akabane virus (AKAV) or Shamonda virus (SHAV) were detected, indicating that neutralizing antibodies against SBV do not cross react with AKAV or SHAV in SNT. ELISA testing of bulk-tank milk samples proved to be convenient and reliable. None of the tested sera was found positive for SBV by real-time RT-PCR, indicating that the sampling was conducted past the viremia stage. This is the first report of SBV circulation in Greece.
Collapse
|
33
|
Evidence of transplacental transmission of bluetongue virus serotype 8 in goats. Vet Microbiol 2013; 166:394-404. [PMID: 23890676 DOI: 10.1016/j.vetmic.2013.06.020] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Revised: 06/16/2013] [Accepted: 06/24/2013] [Indexed: 11/22/2022]
Abstract
During the incursion of bluetongue virus (BTV) serotype 8 in Europe, an increase in the number of abortions in ruminants was observed. Transplacental transmission of BTV-8 in cattle and sheep, with subsequent foetal infection, is a feature of this specific bluetongue serotype. In this study, BTV-8 ability to cross the placental barrier at the beginning of the second third of pregnancy and at the end of pregnancy was investigated in goats in two separate experiments. In the first experiment, nine goats were experimentally infected with BTV-8 at 61 days of pregnancy. Foetuses were collected 21 dpi. BTV-8 was evidenced by real time RT-PCR and by viral isolation using blood from the umbilical cord and the spleens of 3 out of the 13 foetuses. All dams were viraemic (viral isolation) at the moment of sampling of the foetuses. Significant macroscopic or histological lesions could not be observed in foetuses or in their infected dams (notably at the placenta level). In the second experiment, 10 goats were infected with BTV-8 at 135 days of pregnancy. Kids were born by caesarean section at the programmed day of birth (15 dpi). BTV-8 could not be detected by rt-RT-PCR in blood or spleen samples from the kids. This study showed for the first time that BTV-8 transplacental transmission can occur in goats that have been infected at 61 days of pregnancy, with infectious virus recovered from the caprine foetuses. The observed transmission rate was quite high (33%) at this stage of pregnancy. However, it was not possible to demonstrate the existence of BTV-8 transplacental transmission when infection occurred at the end of the goat pregnancy.
Collapse
|
34
|
Evaluation of the humoral immune responses in adult cattle and sheep, 4 and 2.5 years post-vaccination with a bluetongue serotype 8 inactivated vaccine. Vaccine 2013; 31:3783-5. [PMID: 23791548 PMCID: PMC3763366 DOI: 10.1016/j.vaccine.2013.06.033] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2013] [Revised: 05/31/2013] [Accepted: 06/06/2013] [Indexed: 11/22/2022]
Abstract
ELISA antibodies persist in serum and milk for at least 4 years post-vaccination in cattle. ELISA-based milk/serum surveillance is not possible for at least 4 years post-vaccination in cattle, but surveillance is possible in young unvaccinated cattle. Neutralising antibodies persist for at least 4 years post-vaccination (two vaccine doses four weeks apart) in cattle. Neutralising antibodies persist for at least 2.5 years post-vaccination (two vaccine doses one year apart) in sheep. Protection is likely for at least 4 and 2.5 years post-vaccination in cattle and in sheep respectively.
One of the big surprises about the devastating outbreak of bluetongue serotype-8 that spread across Northern and Western Europe between 2006 and 2008 was how relatively quickly the virus was controlled and eradicated from affected countries. This was at least in part attributed to the high levels of vaccine coverage achieved in affected countries. A previous study revealed that neutralising antibodies persisted in the majority of vaccinated cattle for at least 3 years post-vaccination, indicating that cattle are likely to be protected for this time period. The current study revealed that neutralising antibodies persisted in the same group of cattle for up to 4 years post-vaccination, and that neutralising antibodies persisted for up to 2.5 years in sheep that had been vaccinated on two occasions one year apart. These results have implications for future bluetongue surveillance programmes and vaccine control strategies.
Collapse
|
35
|
Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2013; 20:1115-22. [PMID: 23720365 DOI: 10.1128/cvi.00229-13] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Bluetongue virus (BTV), the causative agent of bluetongue in ruminants, is an emerging virus in northern Europe. The 2006 outbreak of BTV serotype 8 (BTV-8) in Europe was marked by an unusual teratogenic effect and a high frequency of clinical signs in cattle. Conventional control strategies targeting small ruminants were therefore extended to include cattle. Since cattle were not routinely vaccinated before 2006, the immune responses to BTV have not been studied extensively in this species. With the aims of developing a subunit vaccine against BTV-8 for differentiation between infected and vaccinated animals based on viral protein 7 (VP7) antibody detection and of improving the current understanding of the immunogenicity of BTV proteins in cattle, the immune responses induced by recombinant VP2 (BTV-8) and nonstructural protein 1 (NS1) and NS2 (BTV-2) were studied. Cows were immunized twice (with a 3-week interval) with the experimental vaccine, a commercial inactivated vaccine, or a placebo. The two vaccines induced similar neutralizing antibody responses to BTV-8. Furthermore, the antibody responses detected against VP2, NS1, and NS2 were strongest in the animals immunized with the experimental vaccine, and for the first time, a serotype cross-reactive antibody response to NS2 was shown in cattle vaccinated with the commercial vaccine. The two vaccines evoked measurable T cell responses against NS1, thereby supporting a bovine cross-reactive T cell response. Finally, VP7 seroconversion was observed after vaccination with the commercial vaccine, as in natural infections, but not after vaccination with the experimental vaccine, indicating that the experimental vaccine may allow the differentiation of vaccinated animals from infected animals regardless of BTV serotype. The experimental vaccine will be further evaluated during a virulent challenge in a high-containment facility.
Collapse
|
36
|
Bréard E, Lara E, Comtet L, Viarouge C, Doceul V, Desprat A, Vitour D, Pozzi N, Cay AB, De Regge N, Pourquier P, Schirrmeier H, Hoffmann B, Beer M, Sailleau C, Zientara S. Validation of a commercially available indirect ELISA using a nucleocapside recombinant protein for detection of Schmallenberg virus antibodies. PLoS One 2013; 8:e53446. [PMID: 23335964 PMCID: PMC3546048 DOI: 10.1371/journal.pone.0053446] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2012] [Accepted: 11/28/2012] [Indexed: 11/23/2022] Open
Abstract
A newly developed Enzym Like Immuno Sorbant Assay (ELISA) based on the recombinant nucleocapsid protein (N) of Schmallenberg virus (SBV) was evaluated and validated for the detection of SBV-specific IgG antibodies in ruminant sera by three European Reference Laboratories. Validation data sets derived from sheep, goat and bovine sera collected in France and Germany (n = 1515) in 2011 and 2012 were categorized according to the results of a virus neutralization test (VNT) or an indirect immuno-flurorescence assay (IFA). The specificity was evaluated with 1364 sera from sheep, goat and bovine collected in France and Belgium before 2009. Overall agreement between VNT and ELISA was 98.9% and 98.3% between VNT and IFA, indicating a very good concordance between the different techniques. Although cross-reactions with other Orthobunyavirus from the Simbu serogroup viruses might occur, it is a highly sensitive, specific and robust ELISA-test validated to detect anti-SBV antibodies. This test can be applied for SBV sero-diagnostics and disease-surveillance studies in ruminant species in Europe.
Collapse
Affiliation(s)
- Emmanuel Bréard
- Virology Unit, French Agency for Food, Environmental and Occupational Health and Safety, Maisons-Alfort, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Liu F, Ge S, Li L, Wu X, Liu Z, Wang Z. Virus-like particles: potential veterinary vaccine immunogens. Res Vet Sci 2012; 93:553-9. [DOI: 10.1016/j.rvsc.2011.10.018] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2011] [Revised: 10/13/2011] [Accepted: 10/20/2011] [Indexed: 11/24/2022]
|
38
|
Zientara S, Amat JP, Sailleau C, Viarouge C, Desprat A, Vitour D, Bréard E. Difficulties in the interpretation of bluetongue RT-PCR results in France. Vet Rec 2012; 170:599. [DOI: 10.1136/vr.100485] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- S. Zientara
- ANSES Alfort; UMR 1161 ANSES/INRA/ENVA 94703 Maisons-Alfort Cédex France
| | - J. P. Amat
- ANSES; Risk Assessment Department; 27-31 Avenue du Général Leclerc Maisons-Alfort France
| | - C. Sailleau
- ANSES Alfort; UMR 1161 ANSES/INRA/ENVA 94703 Maisons-Alfort Cédex France
| | - C. Viarouge
- ANSES Alfort; UMR 1161 ANSES/INRA/ENVA 94703 Maisons-Alfort Cédex France
| | - A. Desprat
- ANSES Alfort; UMR 1161 ANSES/INRA/ENVA 94703 Maisons-Alfort Cédex France
| | - D. Vitour
- ANSES Alfort; UMR 1161 ANSES/INRA/ENVA 94703 Maisons-Alfort Cédex France
| | - E. Bréard
- ANSES Alfort; UMR 1161 ANSES/INRA/ENVA 94703 Maisons-Alfort Cédex France
| |
Collapse
|
39
|
Lorca-Oró C, Pujols J, García-Bocanegra I, Mentaberre G, Granados JE, Solanes D, Fandos P, Galindo I, Domingo M, Lavín S, López-Olvera JR. Protection of Spanish Ibex (Capra pyrenaica) against Bluetongue virus serotypes 1 and 8 in a subclinical experimental infection. PLoS One 2012; 7:e36380. [PMID: 22666321 PMCID: PMC3364256 DOI: 10.1371/journal.pone.0036380] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2011] [Accepted: 04/03/2012] [Indexed: 12/26/2022] Open
Abstract
Many wild ruminants such as Spanish ibex (Capra pyrenaica) are susceptible to Bluetongue virus (BTV) infection, which causes disease mainly in domestic sheep and cattle. Outbreaks involving either BTV serotypes 1 (BTV-1) and 8 (BTV-8) are currently challenging Europe. Inclusion of wildlife vaccination among BTV control measures should be considered in certain species. In the present study, four out of fifteen seronegative Spanish ibexes were immunized with a single dose of inactivated vaccine against BTV-1, four against BTV-8 and seven ibexes were non vaccinated controls. Seven ibexes (four vaccinated and three controls) were inoculated with each BTV serotype. Antibody and IFN-gamma responses were evaluated until 28 days after inoculation (dpi). The vaccinated ibexes showed significant (P<0.05) neutralizing antibody levels after vaccination compared to non vaccinated ibexes. The non vaccinated ibexes remained seronegative until challenge and showed neutralizing antibodies from 7 dpi. BTV RNA was detected in the blood of non vaccinated ibexes from 2 to the end of the study (28 dpi) and in target tissue samples obtained at necropsy (8 and 28 dpi). BTV-1 was successfully isolated on cell culture from blood and target tissues of non vaccinated ibexes. Clinical signs were unapparent and no gross lesions were found at necropsy. Our results show for the first time that Spanish ibex is susceptible and asymptomatic to BTV infection and also that a single dose of vaccine prevents viraemia against BTV-1 and BTV-8 replication.
Collapse
Affiliation(s)
- Cristina Lorca-Oró
- Centre de Recerca en Sanitat Animal, UAB-IRTA, Campus de la Universitat Autònoma de Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Pérez de Diego AC, Sánchez-Cordón PJ, de las Heras AI, Sánchez-Vizcaíno JM. Characterization of the immune response induced by a commercially available inactivated bluetongue virus serotype 1 vaccine in sheep. ScientificWorldJournal 2012; 2012:147158. [PMID: 22619592 PMCID: PMC3349316 DOI: 10.1100/2012/147158] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2011] [Accepted: 12/22/2011] [Indexed: 11/17/2022] Open
Abstract
The protective immune response generated by a commercial monovalent inactivated vaccine against bluetongue virus serotype 1 (BTV1) was studied. Five sheep were vaccinated, boost-vaccinated, and then challenged against BTV1 ALG/2006. RT-PCR did not detect viremia at any time during the experiment. Except a temperature increase observed after the initial and boost vaccinations, no clinical signs or lesions were observed. A specific and protective antibody response checked by ELISA was induced after vaccination and boost vaccination. This specific antibody response was associated with a significant increase in B lymphocytes confirmed by flow cytometry, while significant increases were not observed in T lymphocyte subpopulations (CD4+, CD8+, and WC1+), CD25+ regulatory cells, or CD14+ monocytes. After challenge with BTV1, the antibody response was much higher than during the boost vaccination period, and it was associated with a significant increase in B lymphocytes, CD14+ monocytes, CD25+ regulatory cells, and CD8+ cytotoxic T lymphocytes.
Collapse
Affiliation(s)
- Ana Cristina Pérez de Diego
- VISAVET Health Surveillance Centre and Animal Health Department, Veterinary Faculty, Complutense University of Madrid, Avenida Puerta de Hierro s/n, 28040 Madrid, Spain
| | | | | | | |
Collapse
|
41
|
Oura C, Edwards L, Batten C. Evaluation of the humoral immune response in adult dairy cattle three years after vaccination with a bluetongue serotype 8 inactivated vaccine. Vaccine 2012; 30:112-5. [DOI: 10.1016/j.vaccine.2011.10.100] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2011] [Revised: 10/25/2011] [Accepted: 10/30/2011] [Indexed: 11/30/2022]
|
42
|
|
43
|
Eschbaumer M, Wäckerlin R, Savini G, Zientara S, Sailleau C, Bréard E, Beer M, Hoffmann B. Contamination in bluetongue virus challenge experiments. Vaccine 2011; 29:4299-301. [PMID: 21557978 DOI: 10.1016/j.vaccine.2011.04.049] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2011] [Revised: 04/09/2011] [Accepted: 04/18/2011] [Indexed: 11/19/2022]
Abstract
Five cattle and five sheep that had never been exposed to bluetongue virus (BTV), as well as ten animals that had been experimentally infected with BTV-8, were inoculated with BTV-1. Previous exposure to BTV-8 did not prevent a second infection with another serotype. After the experiment, the BTV-1 preparation was found to be contaminated with BTV-15. The inoculum and blood samples taken during the experiment were analysed by serotype-specific real-time RT-PCR. There was 100-fold less BTV-15 than BTV-1 in the inoculum. Unexpectedly, BTV-15 dominated the infection in cattle that had previously been exposed to BTV-8. In sheep of both groups, on the other hand, BTV-1 prevailed over the contaminant. Regardless of the outcome, the incident demonstrates the need for a thorough contamination screening of virus preparations. For this purpose, two type-specific RT-PCR primer sets for each of the 24 established BTV serotypes as well as Toggenburg Orbivirus were designed.
Collapse
Affiliation(s)
- Michael Eschbaumer
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Südufer 10, 17493 Greifswald-Insel Riems, Germany.
| | | | | | | | | | | | | | | |
Collapse
|